INTRODUCTION
The RUNX family of transcription factors has attracted broad interest due to its involvement in many cancers. RUNX3 is a downstream target of the transforming growth factor-β (TGF-β) pathway, considered a tumour suppressor pathway as components are frequently altered in cancers, especially those of the gastrointestinal tract (1) . Physical interaction between RUNX3 and TGF-β pathway components have been demonstrated (2) . Inherent to the tumour suppressor activity of TGF-β is its ability to induce apoptosis.
Transcriptional up-regulation of Bim, mediated by RUNX3, is observed in TGF-β induced apoptosis (3) . RUNX3 also co-operates with FoxO3a/FKHRL1 to induce apoptosis by activating Bim (4) . Runx3 -/-neonate mice exhibited hyperplasia of the stomach epithelial cells, due to increased proliferation and diminished apoptosis (5) . The epithelial cells were resistant to the growth-suppressive and apoptosis-inducing effects of TGF-β, suggesting that the tumour suppressive activity of RUNX3 is associated with the TGF-β pathway.
Loss of RUNX3 has been reported in many cancers (6) (7) (8) . RUNX3 is inactivated in gastric cancer by hemizygous deletion, promoter hypermethylation, histone modification and protein mislocalization, suggesting a tumour suppressive role of RUNX3 in this malignancy (5, 9, 10) . The discovery of a single point mutation in RUNX3 in a patient sample was one of the most critical observations implicating RUNX3 as a gastric tumour suppressor (5) . A single nucleotide C to T point mutation within the Runt domain of RUNX3 (R122C) completely abolished the tumoursuppressive activity of RUNX3 in nude mice and probably converted it into an oncogene.
RUNX3 point mutations were also identified in two cases of bladder tumour, which abolished the DNA-binding ability of RUNX3 (11) , strongly suggesting that RUNX3 is a tumour suppressor in bladder cancer. The human RUNX3 gene is located at chromosomal locus 1p36 (12) , a region frequently deleted in cancers. In a large percentage of colorectal cancer cell lines and clinical specimens, RUNX3 is silenced by promoter hypermethylation (6, 13) . We have reported that RUNX3, downstream of the tumour suppressive TGF-β pathway, antagonizes the oncogenic Wnt pathway in intestinal carcinogenesis (14) . RUNX3 and TCF4 bind directly to each other and form a ternary complex with β-catenin, negatively regulating Wnt signalling by inhibiting the transcriptional activity of β-catenin/TCF4 on promoters of Wnt target genes.
Bone morphogenetic proteins (BMPs) belong to the TGF-β superfamily and are multifunctional proteins with a wide range of biological activities, including proliferation and apoptosis. Two type I receptors, BMP receptor Ia (BMPRIa) and BMP receptor Ib (BMPRIb), and one type II receptor, BMP receptor II (BMPRII) have been identified (15) (16) (17) . BMP binding induces oligomerization of the receptor complex and type II receptor phosphorylates type I receptor. The receptor complex phosphorylates the BMPspecific Smads, Smad1, Smad5 and Smad8, which complexes with Smad4 and translocates to the nucleus to activate gene expression that mediates the biological action of BMPs.
BMPs have been shown to function as tumour suppressors in cancer, including gastric and pancreatic cancer (18, 19) . Recent findings suggest the involvement of BMPs in colon cancer. Frequent germline mutations in the SMAD4 gene were found in colon cancer patients (20) . The most compelling evidence for the role of BMPs in colon cancer is the discovery of germline mutations in BMPRIa gene in patients with a rare inherited gastrointestinal cancer predisposition syndrome, familial juvenile polyposis (JP) (21) .
Inhibiting BMP signalling in epithelial cells by transgenic overexpression of noggin, a BMP antagonist, resulted in the formation of ectopic crypts and polyps in the mouse intestine, mimicking the intestinal histopathology of JP (22) . Another study showed that BMP suppression also causes JP-type gastric hamartoma development (23). Similarly, conditional inactivation of BMPRIa and BMPRII resulted in hyperplasia and development of harmatomatous polyps in the colon, recapitulating the human JP syndrome (24, 25) . These findings further reinforce the role of BMP signalling in colonic malignancy.
Here, we investigated a potential role for RUNX3 as a tumour suppressor in colorectal cancer, downstream of the BMP pathway. In this paper, we address the mechanism through which RUNX3 exerts its tumour suppressive activity in response to BMP in colorectal cancer cells. Involvement of both BMP and Wnt pathways is demonstrated, further strengthening the recurrent theme of crosstalk between these two pathways in colorectal cancer.
MATERIALS AND METHODS

Cell culture and Reagents
Colorectal cancer cell lines, HT-29, HCT116, SW480, DLD1, WiDr, Ls174T, Colo205, Colo320, RKO, LoVo, SW403, Colo201, CaCo2, SW837, Ls513, Ls1034 and SW620 were obtained from American Type Culture Collection (ATCC). Five colorectal cancer cell lines, OUMS23, CCK81, CoCM1, RCM1 and HCC56 were obtained from Japanese Collection of Research Bioresources (JCRB). Where indicated, cells were treated with 100ng/ml of human recombinant BMP2 or BMP4, or 10ng/ml of TGF-β (R&D Systems). As a control, cells were treated with the same volume of vehicle, 0.1% bovine serum albumin in 4mM HCl, used to reconstitute BMPs and TGF-β.
Transfections
RUNX3 mutants were constructed as described in Ito et al (14) . Transfection of plasmids into 293T cells were performed using LipofectAMINE 2000 (Invitrogen).
Transfection of plasmids and siRNAs into HT-29 was performed using FuGene HD RNA and protein were then extracted.
Promoter studies
The c-Myc promoter construct has been previously described (26) . HT-29 cells were co-transfected with the c-Myc promoter and a renilla luciferase construct, pRL-basic, for normalization of transfection efficiency. 48 hours post-transfection, cells were treated with BMP for 24 hours. Where BMP treatment was unnecessary, cells were lysed 48 hours post-transfection. Luciferase activity was determined using the Dual-Luciferase Reporter Assay (Promega). Mutagenesis of the c-Myc promoter was performed using Quik-Change Site-Directed mutagenesis kit (Stratagene) and confirmed by DNA sequencing. To assay TCF-mediated transcription, a TOP/FOPflash reporter (Upstate) was used. All experiments were performed in triplicates and independently repeated.
RNA extraction and reverse transcription
Total RNA was extracted from cells using RNeasy Mini Kit (Qiagen). To avoid genomic DNA contamination, DNase digestion was performed using RNase-free DNase set (Qiagen). cDNA synthesis was performed with 1µg of total RNA, using Omniscript Reverse Transcription Kit (Qiagen) and oligo(dT) 15 primers (Roche).
Real-time PCR analysis
Real-time PCR was carried out using the ABI-PRISM 7500 Fast Sequence Detection System and ABI Taqman gene expression system (Applied Biosystems).
Relative quantitation was calculated by ΔΔC t method, normalized to either GAPDH or β-actin, and analysed using the Sequence Detection System 7500 Fast System v.1.4.0 software (Applied Biosystems). All analyses were done in triplicates. For gene expression profiling, a gene is defined as undetectable when no C T value can be obtained, indicating that mRNA is completely absent. We define a low expressing gene when C T value is above 30. We define a moderate expression when C T value is between 25-30 and a high expression when C T value is lower than 25.
Western Blot analysis
Nuclear extracts were prepared using NE-PER nuclear and cytoplasmic extraction reagents (Pierce), according to the manufacturer's instructions. Lysates containing 30µg of nuclear proteins or 50µg of total cellular proteins were analyzed by Western Blot using anti-phospho Smad-1/5 (Upstate), 5G4 anti-RUNX3 (9), anti-histone H3 (Upstate) and anti-β-actin (Sigma) antibodies. Immunoreactivity was visualised either by ECL chemiluminescence (Amersham Biosciences) or by Supersignal West Femto Maximum Sensitivity Substrate (Pierce).
Apoptosis detection
Apoptosis was examined using an AnnexinV-fluorescein isothiocyanate (FITC) apoptosis detection kit II (BD Biosciences) as described (4) . Cells were analyzed by flow cytometry using a FACS Vantage (BD Biosciences) and FlowJo software (BD Biosciences).
Chromatin Immunoprecipitation
Chromatin Immunoprecipitation (ChIP) was performed using the ChIP assay kit (Upstate), dephosphorylated β-catenin antibody (Alexis) or normal rabbit IgG. Primers used to amplify DNA fragments containing a TCF consensus site in the c-Myc promoter were forward, 5'-GTGAATACACGTTTGCGGGTTAC-3' and reverse, 5'-AGAGACCCTTGTGAAAAAAACCG-3' (27) .
Statistical analysis
Statistical evaluation was performed using the student's unpaired t-test. Data are presented as mean ± SD. A value of p < 0.05 was considered statistically significant. For proliferation over time, ANOVA analysis followed by Bonferroni's Multiple Comparison Test was used for statistical evaluation. All tests were applied using the GraphPad Prism software.
RESULTS
Altered gene expression of RUNX3 in colorectal cancer cells
The gene expression profile of RUNX1, RUNX2, RUNX3 and PEBP2β was examined in a panel of 22 colorectal cancer cell lines (Table 1) . RUNX1, RUNX2 and PEBP2β were expressed at moderate to high levels in all cell lines, except Colo205, CaCo2 and SW620 which expressed RUNX2 at a very low level. Interestingly, frequent loss of RUNX3 expression was observed. RUNX3 was expressed at decreased or undetectable levels in 9 of the 22 cell lines (40.9%). Expression of RUNX3 was undetectable in RKO and was expressed at low levels in HT-29, DLD1, WiDr, Ls174T, LoVo, OUMS23, Ls1034 and HCC56.
Human BMP receptors and Smad signalling components are expressed in majority of colorectal cancer cells
As a first step to studying BMP signalling in colorectal cancer, we characterized expression of BMP receptors and Smads in colorectal cancer cell lines (Table 1 BMPs have been shown to attenuate cell growth by regulating apoptosis (28) . In the absence of BMP, the percentage of apoptotic cells was 1.9% ( Figure 1D ). When cells were treated with BMP2 and BMP4, the percentage of apoptotic cells was 3.0% and 2.2% respectively. Since BMPs did not induce apoptosis in HT-29 cells significantly, growth inhibitory effect of BMP is not associated with increased apoptosis.
BMP treatment induced RUNX3 expression in colorectal cancer cells
Changes in RUNX expression levels after BMP treatment were determined.
Interestingly, RUNX3 gene expression was induced by 4 fold and 8 fold, when HT-29 cells were treated with BMP2 and BMP4 respectively (Figure 2A ). There were no changes in RUNX1 and RUNX2 expression. An increase in RUNX3 protein expression was also observed ( Figure 2B ). Both BMP and TGF-β have been reported to elicit a growth suppressive effect in colorectal cancer cells (29, 30) . In addition, TGF-β and BMP have been reported to induce RUNX2 (31) . However, TGF-β failed to upregulate RUNX3 in HT-29 (data not shown). Therefore, these observations suggest that RUNX3 is the only member of the RUNX family specifically regulated by BMP.
BMP and RUNX3 attenuate the transcriptional potential of β-catenin/TCF4 in Wnt signalling
We investigated the effect of BMP on Wnt signalling using the TOPflash/FOPflash reporter system. Elevated TOPflash activity correlates with β-catenin /TCF transcriptional activity and Wnt signalling (32) . BMP had a suppressive effect on TOPflash activity but had no effect on FOPflash activity ( Figure 2C ). These data show that BMP inhibits the β-catenin/TCF-mediated transcriptional activation.
Next, we examined the transactivation of β-catenin/TCF4 in the presence of RUNX3 using the TOPflash/FOPflash reporter system. In HT-29, which expresses a low level of RUNX3, increasing amounts of exogenous RUNX3 progressively suppressed TOPflash activity ( Figure 2D ). Therefore, RUNX3 also inhibits the β-catenin/TCFmediated transcriptional activation in a dose-dependent manner.
BMP treatment repressed c-Myc mRNA expression by transcriptional mechanisms
Since c-Myc is a well known β-catenin/TCF-4 transcriptional target gene (33) From the results shown in Figure 3C and 3D, it can be concluded that the TCF- 
DISCUSSION
BMPs have been reported to be growth-inhibitory in cancers, including breast, gastric, colon and thyroid cancer (29, 35) . However, the molecular mechanisms underlying its growth suppressive effect is not well-defined. In this study, the antiproliferative effect of BMPs was examined in colorectal cancer. We used HT-29, a colorectal adenocarcinoma cell line, as a model to examine BMP signalling in colorectal cancer as it expresses BMP-specific Smads and receptors and BMP signalling is intact. Additionally, RUNX1 was identified as a downstream target of the TGF-β/BMP pathway in the haematopoietic system (41) . In this study, up-regulation of RUNX3 was observed when HT-29 cells were treated with BMP. We demonstrate that RUNX3, but not RUNX1 and RUNX2, showed BMP-dependent expression. TGF-β had no effect on RUNX3 expression. These results suggest that induction of RUNX3 by BMP is unique and specific to RUNX3.
In this study, we show that BMP inhibits c-Myc transcriptional activity and expression in a RUNX3-dependent manner. MYC is located at 8q24, a region reported to propose that this is due, in part, to the mechanism suggested by Ito et al (14) , where RUNX3 and TCF4 bind directly to each other to form a ternary complex with β-catenin. The failure to obtain a more pronounced effect is probably because colorectal cancer cells do not respond well to BMP's growth inhibitory effect (44) . This could be attributed to the fact that some transformed cells express high levels of BMP inhibitors (45) .
Alternatively, some cells also secrete endogenous BMP. Colon cancer cells, including HT-29, have been shown to secrete BMP4 (46) . This is consistent with results shown in Figure 1A supporting the notion of a low basal level of BMP signalling in HT-29. Given endogenous BMP production in HT-29, it is not surprising that only a small increase in BMP-specific transcriptional activity is observed when cells were treated with exogenous BMP.
In this study, we observed differential effects of BMP2 and BMP4. Although they are highly homologous, divergent roles for BMP2 and BMP4 have been described (47) .
Thus, it is not surprising that the effect of BMP2 and BMP4 in c-Myc transactivation is dissimilar. Since there are no fundamental differences in the signalling pathways used by both BMP2 and BMP4 and they bind to the same receptors, this disparity could be due to different binding affinity of BMPs on these receptors. This could lead to differences in downstream signal transduction and variation in biological responses to BMPs.
In conclusion, our work has identified RUNX3 as a novel downstream target of the BMP pathway. We show that RUNX3 exerts its tumour suppressor effect downstream of BMP by inhibiting c-Myc. This study gives new insight into the mechanisms in which BMP suppresses cell growth and c-Myc expression in colorectal cancer. A disruption of BMP signalling leads to the deregulation of the intricate balance between promotion and inhibition of proliferation, which in turn is associated with increased tumorigenesis and colon cancer. It is intriguing to speculate that restoration of BMP pathway could contribute to new therapeutic strategies for colorectal cancer.
TABLE 1
Expression of BMP signalling pathway components and RUNX genes in colorectal cancer cells lines.
Legend: ++, high expression; +, moderate expression; -, very low expression; --, undetectable. HT-29 cells were co-transfected with TOPflash or FOPflash, and increasing amounts of RUNX3. All firefly luciferase activities were normalised to the renilla luciferase activity of pRL-basic, which was used as an internal transfection control. 
Methylation-specific PCR (MSP)
Methylation-specific PCR (MSP) was performed in CpG-rich regions of c-Myc to evaluate the impact of RUNX3 on DNA methylation of the c-Myc promoter. HT-29 and HCT116 cells were transfected with control siRNA or siRNA against RUNX3 for 48 hours. Extraction of genomic DNA from HT-29 and HCT116 cells was then performed using the QIAGEN genomic DNA kits for preparation of genomic DNA from cultured cells (Qiagen) according to the manufacturer's instructions. Bisulphite conversion of the DNA was carried out using the EZ DNA-Methylation-Gold Kit (Zymo Research) according to the manufacturer's instructions. The chemically modified DNA was then used as a template for PCR. The primer sets used for detection of methylated DNA were forward, 5'-tagaattggattggggtaaa -3' and reverse, 5'-cgaccgaaaatcaacgcgaat -3'. The primer sets used for detection of unmethylated DNA were forward, 5'-tagaattggattggggtaaa -3' and reverse, 5'-ccaaccaaaaatcaacatgaat -3', as reported previously (1).
Matrigel invasion assay
Invasion assays were performed using the BD BioCoat Matrigel Invasion Chamber (BD Biosciences) according to the manufacturer's instructions. Briefly, serum-free DMEM containing 100ng/ml of BMP2 or BMP4 was added to the bottom chamber to serve as a chemoattractant. After 24 hours of incubation, non-migrating cells were removed from the upper chamber using a cotton swab. Cells which migrated through the Matrigel were fixed, stained and counted. Mean values for four randomly selected fields were obtained for each sample. All experiments were repeated three times. 
